Skip to main content
ImmuneCited

Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents.

Wolfgang Kamin, Lidia I Ilyenko, Fathi A Malek, Meinhard Kieser
RCT Pediatrics international : official journal of the Japan Pediatric Society 2012 56 citations
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'pmid\u003D22360575'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Type d'étude
Randomized Controlled Trial
Taille de l'échantillon
220
Population
Children and adolescents with acute bronchitis
Durée
1 weeks
Intervention
Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. 3x10-30 drops/day (age-adjusted)
Comparateur
Placebo drops
Critère de jugement principal
Bronchitis Severity Score (BSS) change
Direction de l'effet
Positive
Risque de biais
Low

Abstract

BACKGROUND: The aim of this trial was to investigate the efficacy and tolerability of EPs 7630, a herbal drug preparation from Pelargonium sidoides, in children and adolescents suffering from acute bronchitis, outside the strict indication for antibiotics. METHODS: A total of 220 patients with acute bronchitis were randomized and given either verum containing EPs 7630 (1-6 years/>6-12 years/>12-18 years: 3 × 10/3 × 20/3 × 30 drops/day) or matching placebo for 7 days. The main outcome measure was the change in the total score of bronchitis-specific symptoms (BSS) from day 0 to day 7. RESULTS: The decrease in the BSS total score was significantly higher for EPs 7630 compared to placebo (change day 0-day 7: 4.4 ± 1.6 vs 2.9 ± 1.4 points; P < 0.0001). Improvements were most pronounced for 'coughing' and 'rales at auscultation'. Tolerability was similarly good in both groups. CONCLUSIONS: EPs 7630 proved to be an efficacious and well-tolerated option for the treatment of acute bronchitis in children and adolescents outside the strict indication for antibiotics.

En bref

The aim of this trial was to investigate the efficacy and tolerability of EPs 7630, a herbal drug preparation from Pelargonium sidoides, in children and adolescents suffering from acute bronchitis outside the strict indication for antibiotics.

Used In Evidence Reviews

Similar Papers